Analysts have been eager to weigh in on the Healthcare sector with new ratings on Community Health (CYH – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Ansell (ANSLF – Research Report).
Community Health (CYH)
RBC Capital analyst Ben Hendrix maintained a Buy rating on Community Health yesterday and set a price target of $6.00. The company’s shares closed last Wednesday at $2.90, close to its 52-week low of $2.01.
According to TipRanks.com, Hendrix is a 3-star analyst with an average return of
Currently, the analyst consensus on Community Health is a Moderate Buy with an average price target of $4.57, implying a 37.2% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $6.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Crispr Therapeutics AG (CRSP)
RBC Capital analyst Luca Issi maintained a Hold rating on Crispr Therapeutics AG yesterday and set a price target of $66.00. The company’s shares closed last Wednesday at $82.41, close to its 52-week high of $90.18.
According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of
Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $86.45, a 4.8% upside from current levels. In a report issued on February 14, Wolfe Research also initiated coverage with a Hold rating on the stock.
Ansell (ANSLF)
In a report released today, Vanessa Thomson from Jefferies maintained a Hold rating on Ansell, with a price target of A$26.00. The company’s shares closed last Wednesday at $16.30.
Thomson has an average return of
According to TipRanks.com, Thomson is ranked #2071 out of 8729 analysts.
Ansell has an analyst consensus of Hold, with a price target consensus of $17.58.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYH:
